SrasV1, PascalFrancis, Curation, bibRecord, 000970

Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors

Identifieur interne : 000970 ( PascalFrancis/Curation ); précédent : 000969; suivant : 000971

Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors

Auteurs : Andy Kilianski [États-Unis] ; Susan C. Baker [États-Unis]

Source :

Antiviral research [ 0166-3542 ] ; 2014.

RBID : Pascal:14-0035776

Descripteurs français

Pascal (Inist)
- In vitro, Cellule, Antiviral, Criblage, Dépistage, Virus syndrome respiratoire aigu sévère, Spectre, RNA-directed RNA polymerase, Inhibiteur d'entrée, Syndrome respiratoire du Moyen-Orient.

English descriptors

KwdEn :
- Antiviral, Cell, Entry inhibitor, In vitro, Medical screening, Middle East respiratory syndrome, RNA-directed RNA polymerase, Screening, Severe acute respiratory syndrome virus, Spectrum.

Abstract

To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.".

A01	`01`	`1`		`@0 0166-3542`
A02	`01`			`@0 ARSRDR`
A03		`1`		`@0 Antivir. res.`
A05				`@2 101`
A08	`01`	`1`	`ENG`	`@1 Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors`
A11	`01`	`1`		`@1 KILIANSKI (Andy)`
A11	`02`	`1`		`@1 BAKER (Susan C.)`
A14	`01`			`@1 Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine @2 Maywood, IL 60153 @3 USA @Z 1 aut. @Z 2 aut.`
A20				`@1 105-112`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18839 @5 354000500744760140`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.3/4`
A47	`01`	`1`		`@0 14-0035776`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral research`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.".
C02	`01`	`X`		`@0 002B02S05`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 In vitro @5 01`
C03	`01`	`X`	`ENG`	`@0 In vitro @5 01`
C03	`01`	`X`	`SPA`	`@0 In vitro @5 01`
C03	`02`	`X`	`FRE`	`@0 Cellule @5 02`
C03	`02`	`X`	`ENG`	`@0 Cell @5 02`
C03	`02`	`X`	`SPA`	`@0 Célula @5 02`
C03	`03`	`X`	`FRE`	`@0 Antiviral @5 03`
C03	`03`	`X`	`ENG`	`@0 Antiviral @5 03`
C03	`03`	`X`	`SPA`	`@0 Antiviral @5 03`
C03	`04`	`X`	`FRE`	`@0 Criblage @5 04`
C03	`04`	`X`	`ENG`	`@0 Screening @5 04`
C03	`04`	`X`	`SPA`	`@0 Cernido @5 04`
C03	`05`	`X`	`FRE`	`@0 Dépistage @5 05`
C03	`05`	`X`	`ENG`	`@0 Medical screening @5 05`
C03	`05`	`X`	`SPA`	`@0 Descubrimiento @5 05`
C03	`06`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 06`
C03	`06`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 06`
C03	`06`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 06`
C03	`07`	`X`	`FRE`	`@0 Spectre @5 07`
C03	`07`	`X`	`ENG`	`@0 Spectrum @5 07`
C03	`07`	`X`	`SPA`	`@0 Espectro @5 07`
C03	`08`	`X`	`FRE`	`@0 RNA-directed RNA polymerase @2 FE @5 08`
C03	`08`	`X`	`ENG`	`@0 RNA-directed RNA polymerase @2 FE @5 08`
C03	`08`	`X`	`SPA`	`@0 RNA-directed RNA polymerase @2 FE @5 08`
C03	`09`	`X`	`FRE`	`@0 Inhibiteur d'entrée @4 CD @5 96`
C03	`09`	`X`	`ENG`	`@0 Entry inhibitor @4 CD @5 96`
C03	`09`	`X`	`SPA`	`@0 Inhibidor de entrada @4 CD @5 96`
C03	`10`	`X`	`FRE`	`@0 Syndrome respiratoire du Moyen-Orient @4 CD @5 97`
C03	`10`	`X`	`ENG`	`@0 Middle East respiratory syndrome @4 CD @5 97`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Nucleotidyltransferases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Nucleotidyltransferases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Nucleotidyltransferases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Transferases @2 FE`
C07	`06`	`X`	`ENG`	`@0 Transferases @2 FE`
C07	`06`	`X`	`SPA`	`@0 Transferases @2 FE`
C07	`07`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`07`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`07`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`08`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 37`
C07	`08`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`08`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`09`	`X`	`FRE`	`@0 Virose @5 38`
C07	`09`	`X`	`ENG`	`@0 Viral disease @5 38`
C07	`09`	`X`	`SPA`	`@0 Virosis @5 38`
C07	`10`	`X`	`FRE`	`@0 Infection`
C07	`10`	`X`	`ENG`	`@0 Infection`
C07	`10`	`X`	`SPA`	`@0 Infección`
N21				`@1 041`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000017

Links to Exploration step

Pascal:14-0035776

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors</title>
<author><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1>
<s2>Maywood, IL 60153</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1>
<s2>Maywood, IL 60153</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0035776</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0035776 INIST</idno>
<idno type="RBID">Pascal:14-0035776</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000017</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000970</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors</title>
<author><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1>
<s2>Maywood, IL 60153</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C." last="Baker">Susan C. Baker</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1>
<s2>Maywood, IL 60153</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Cell</term>
<term>Entry inhibitor</term>
<term>In vitro</term>
<term>Medical screening</term>
<term>Middle East respiratory syndrome</term>
<term>RNA-directed RNA polymerase</term>
<term>Screening</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Spectrum</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>In vitro</term>
<term>Cellule</term>
<term>Antiviral</term>
<term>Criblage</term>
<term>Dépistage</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Spectre</term>
<term>RNA-directed RNA polymerase</term>
<term>Inhibiteur d'entrée</term>
<term>Syndrome respiratoire du Moyen-Orient</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.".</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0>
</fA01>
<fA02 i1="01"><s0>ARSRDR</s0>
</fA02>
<fA03 i2="1"><s0>Antivir. res.</s0>
</fA03>
<fA05><s2>101</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KILIANSKI (Andy)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BAKER (Susan C.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine</s1>
<s2>Maywood, IL 60153</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>105-112</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18839</s2>
<s5>354000500744760140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.3/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0035776</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral research</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.".</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>In vitro</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>In vitro</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>In vitro</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cellule</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cell</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Célula</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Criblage</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Screening</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Cernido</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dépistage</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Medical screening</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Descubrimiento</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Spectre</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Spectrum</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Espectro</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>RNA-directed RNA polymerase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>RNA-directed RNA polymerase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>RNA-directed RNA polymerase</s0>
<s2>FE</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Inhibiteur d'entrée</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Entry inhibitor</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inhibidor de entrada</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Syndrome respiratoire du Moyen-Orient</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Middle East respiratory syndrome</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Nucleotidyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nucleotidyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Nucleotidyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Virose</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Viral disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Virosis</s0>
<s5>38</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>041</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000970 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000970 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0035776
   |texte=   Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors

Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri